<!DOCTYPE html>
<!-- Generated by pkgdown: do not edit by hand --><html lang="en"><head><meta http-equiv="Content-Type" content="text/html; charset=UTF-8"><meta charset="utf-8"><meta http-equiv="X-UA-Compatible" content="IE=edge"><meta name="viewport" content="width=device-width, initial-scale=1, shrink-to-fit=no"><meta name="description" content="The function optimal_bias of the drugdevelopR package enables planning of phase II/III drug development programs with optimal sample size allocation and go/no-go decision rules including methods for discounting of phase II results for time-to-event endpoints (Preussler et. al, 2020).
The discounting may be necessary as programs that proceed to phase III can be overoptimistic about the treatment effect (i.e. they are biased).
The assumed true treatment effects can be assumed fixed (planning is then also possible via user friendly R Shiny App: bias) or modelled by a prior distribution.
The R Shiny application prior visualizes the prior distributions used in this package.
Fast computing is enabled by parallel programming."><title>Optimal phase II/III drug development planning for time-to-event endpoints
when discounting phase II results — optimal_bias • drugdevelopR</title><script src="../deps/jquery-3.6.0/jquery-3.6.0.min.js"></script><meta name="viewport" content="width=device-width, initial-scale=1, shrink-to-fit=no"><link href="../deps/bootstrap-5.2.2/bootstrap.min.css" rel="stylesheet"><script src="../deps/bootstrap-5.2.2/bootstrap.bundle.min.js"></script><!-- Font Awesome icons --><link rel="stylesheet" href="https://cdnjs.cloudflare.com/ajax/libs/font-awesome/5.12.1/css/all.min.css" integrity="sha256-mmgLkCYLUQbXn0B1SRqzHar6dCnv9oZFPEC1g1cwlkk=" crossorigin="anonymous"><link rel="stylesheet" href="https://cdnjs.cloudflare.com/ajax/libs/font-awesome/5.12.1/css/v4-shims.min.css" integrity="sha256-wZjR52fzng1pJHwx4aV2AO3yyTOXrcDW7jBpJtTwVxw=" crossorigin="anonymous"><!-- bootstrap-toc --><script src="https://cdn.jsdelivr.net/gh/afeld/bootstrap-toc@v1.0.1/dist/bootstrap-toc.min.js" integrity="sha256-4veVQbu7//Lk5TSmc7YV48MxtMy98e26cf5MrgZYnwo=" crossorigin="anonymous"></script><!-- headroom.js --><script src="https://cdnjs.cloudflare.com/ajax/libs/headroom/0.11.0/headroom.min.js" integrity="sha256-AsUX4SJE1+yuDu5+mAVzJbuYNPHj/WroHuZ8Ir/CkE0=" crossorigin="anonymous"></script><script src="https://cdnjs.cloudflare.com/ajax/libs/headroom/0.11.0/jQuery.headroom.min.js" integrity="sha256-ZX/yNShbjqsohH1k95liqY9Gd8uOiE1S4vZc+9KQ1K4=" crossorigin="anonymous"></script><!-- clipboard.js --><script src="https://cdnjs.cloudflare.com/ajax/libs/clipboard.js/2.0.6/clipboard.min.js" integrity="sha256-inc5kl9MA1hkeYUt+EC3BhlIgyp/2jDIyBLS6k3UxPI=" crossorigin="anonymous"></script><!-- search --><script src="https://cdnjs.cloudflare.com/ajax/libs/fuse.js/6.4.6/fuse.js" integrity="sha512-zv6Ywkjyktsohkbp9bb45V6tEMoWhzFzXis+LrMehmJZZSys19Yxf1dopHx7WzIKxr5tK2dVcYmaCk2uqdjF4A==" crossorigin="anonymous"></script><script src="https://cdnjs.cloudflare.com/ajax/libs/autocomplete.js/0.38.0/autocomplete.jquery.min.js" integrity="sha512-GU9ayf+66Xx2TmpxqJpliWbT5PiGYxpaG8rfnBEk1LL8l1KGkRShhngwdXK1UgqhAzWpZHSiYPc09/NwDQIGyg==" crossorigin="anonymous"></script><script src="https://cdnjs.cloudflare.com/ajax/libs/mark.js/8.11.1/mark.min.js" integrity="sha512-5CYOlHXGh6QpOFA/TeTylKLWfB3ftPsde7AnmhuitiTX4K5SqCLBeKro6sPS8ilsz1Q4NRx3v8Ko2IBiszzdww==" crossorigin="anonymous"></script><!-- pkgdown --><script src="../pkgdown.js"></script><meta property="og:title" content="Optimal phase II/III drug development planning for time-to-event endpoints
when discounting phase II results — optimal_bias"><meta property="og:description" content="The function optimal_bias of the drugdevelopR package enables planning of phase II/III drug development programs with optimal sample size allocation and go/no-go decision rules including methods for discounting of phase II results for time-to-event endpoints (Preussler et. al, 2020).
The discounting may be necessary as programs that proceed to phase III can be overoptimistic about the treatment effect (i.e. they are biased).
The assumed true treatment effects can be assumed fixed (planning is then also possible via user friendly R Shiny App: bias) or modelled by a prior distribution.
The R Shiny application prior visualizes the prior distributions used in this package.
Fast computing is enabled by parallel programming."><!-- mathjax --><script src="https://cdnjs.cloudflare.com/ajax/libs/mathjax/2.7.5/MathJax.js" integrity="sha256-nvJJv9wWKEm88qvoQl9ekL2J+k/RWIsaSScxxlsrv8k=" crossorigin="anonymous"></script><script src="https://cdnjs.cloudflare.com/ajax/libs/mathjax/2.7.5/config/TeX-AMS-MML_HTMLorMML.js" integrity="sha256-84DKXVJXs0/F8OTMzX4UR909+jtl4G7SPypPavF+GfA=" crossorigin="anonymous"></script><!--[if lt IE 9]>
<script src="https://oss.maxcdn.com/html5shiv/3.7.3/html5shiv.min.js"></script>
<script src="https://oss.maxcdn.com/respond/1.4.2/respond.min.js"></script>
<![endif]--></head><body>
    <a href="#main" class="visually-hidden-focusable">Skip to contents</a>
    

    <nav class="navbar fixed-top navbar-light navbar-expand-lg bg-light"><div class="container">
    
    <a class="navbar-brand me-2" href="../index.html">drugdevelopR</a>

    <small class="nav-text text-muted me-auto" data-bs-toggle="tooltip" data-bs-placement="bottom" title="">1.0.0</small>

    
    <button class="navbar-toggler" type="button" data-bs-toggle="collapse" data-bs-target="#navbar" aria-controls="navbar" aria-expanded="false" aria-label="Toggle navigation">
      <span class="navbar-toggler-icon"></span>
    </button>

    <div id="navbar" class="collapse navbar-collapse ms-3">
      <ul class="navbar-nav me-auto"><li class="active nav-item">
  <a class="nav-link" href="../reference/index.html">Reference</a>
</li>
<li class="nav-item dropdown">
  <a href="#" class="nav-link dropdown-toggle" data-bs-toggle="dropdown" role="button" aria-expanded="false" aria-haspopup="true" id="dropdown-articles">Articles</a>
  <div class="dropdown-menu" aria-labelledby="dropdown-articles">
    <a class="dropdown-item" href="../articles/Introduction-to-drugdevelopR.html">Introduction to planning phase II and phase III trials with drugdevelopR</a>
    <a class="dropdown-item" href="../articles/Package_validation.html">Package validation</a>
    <div class="dropdown-divider"></div>
    <a class="dropdown-item" href="../articles/index.html">More articles...</a>
  </div>
</li>
<li class="nav-item">
  <a class="nav-link" href="../news/index.html">Changelog</a>
</li>
      </ul><form class="form-inline my-2 my-lg-0" role="search">
        <input type="search" class="form-control me-sm-2" aria-label="Toggle navigation" name="search-input" data-search-index="../search.json" id="search-input" placeholder="Search for" autocomplete="off"></form>

      <ul class="navbar-nav"><li class="nav-item">
  <a class="external-link nav-link" href="https://github.com/Sterniii3/drugdevelopR/" aria-label="github">
    <span class="fab fa fab fa-github fa-lg"></span>
     
  </a>
</li>
      </ul></div>

    
  </div>
</nav><div class="container template-reference-topic">
<div class="row">
  <main id="main" class="col-md-9"><div class="page-header">
      <img src="" class="logo" alt=""><h1>Optimal phase II/III drug development planning for time-to-event endpoints
when discounting phase II results</h1>
      <small class="dont-index">Source: <a href="https://github.com/Sterniii3/drugdevelopR/blob/HEAD/R/optimal_bias.R" class="external-link"><code>R/optimal_bias.R</code></a></small>
      <div class="d-none name"><code>optimal_bias.Rd</code></div>
    </div>

    <div class="ref-description section level2">
    <p>The function <code>optimal_bias</code> of the drugdevelopR package enables planning of phase II/III drug development programs with optimal sample size allocation and go/no-go decision rules including methods for discounting of phase II results for time-to-event endpoints (Preussler et. al, 2020).
The discounting may be necessary as programs that proceed to phase III can be overoptimistic about the treatment effect (i.e. they are biased).
The assumed true treatment effects can be assumed fixed (planning is then also possible via user friendly R Shiny App: <a href="https://web.imbi.uni-heidelberg.de/bias/" class="external-link">bias</a>) or modelled by a prior distribution.
The R Shiny application <a href="https://web.imbi.uni-heidelberg.de/prior/" class="external-link">prior</a> visualizes the prior distributions used in this package.
Fast computing is enabled by parallel programming.</p>
    </div>

    <div class="section level2">
    <h2 id="ref-usage">Usage<a class="anchor" aria-label="anchor" href="#ref-usage"></a></h2>
    <div class="sourceCode"><pre class="sourceCode r"><code><span><span class="fu">optimal_bias</span><span class="op">(</span></span>
<span>  <span class="va">w</span>,</span>
<span>  <span class="va">hr1</span>,</span>
<span>  <span class="va">hr2</span>,</span>
<span>  <span class="va">id1</span>,</span>
<span>  <span class="va">id2</span>,</span>
<span>  <span class="va">d2min</span>,</span>
<span>  <span class="va">d2max</span>,</span>
<span>  <span class="va">stepd2</span>,</span>
<span>  <span class="va">hrgomin</span>,</span>
<span>  <span class="va">hrgomax</span>,</span>
<span>  <span class="va">stephrgo</span>,</span>
<span>  adj <span class="op">=</span> <span class="st">"both"</span>,</span>
<span>  lambdamin <span class="op">=</span> <span class="cn">NULL</span>,</span>
<span>  lambdamax <span class="op">=</span> <span class="cn">NULL</span>,</span>
<span>  steplambda <span class="op">=</span> <span class="cn">NULL</span>,</span>
<span>  alphaCImin <span class="op">=</span> <span class="cn">NULL</span>,</span>
<span>  alphaCImax <span class="op">=</span> <span class="cn">NULL</span>,</span>
<span>  stepalphaCI <span class="op">=</span> <span class="cn">NULL</span>,</span>
<span>  <span class="va">alpha</span>,</span>
<span>  <span class="va">beta</span>,</span>
<span>  <span class="va">xi2</span>,</span>
<span>  <span class="va">xi3</span>,</span>
<span>  <span class="va">c2</span>,</span>
<span>  <span class="va">c3</span>,</span>
<span>  <span class="va">c02</span>,</span>
<span>  <span class="va">c03</span>,</span>
<span>  K <span class="op">=</span> <span class="cn">Inf</span>,</span>
<span>  N <span class="op">=</span> <span class="cn">Inf</span>,</span>
<span>  S <span class="op">=</span> <span class="op">-</span><span class="cn">Inf</span>,</span>
<span>  steps1 <span class="op">=</span> <span class="fl">1</span>,</span>
<span>  stepm1 <span class="op">=</span> <span class="fl">0.95</span>,</span>
<span>  stepl1 <span class="op">=</span> <span class="fl">0.85</span>,</span>
<span>  <span class="va">b1</span>,</span>
<span>  <span class="va">b2</span>,</span>
<span>  <span class="va">b3</span>,</span>
<span>  fixed <span class="op">=</span> <span class="cn">FALSE</span>,</span>
<span>  num_cl <span class="op">=</span> <span class="fl">1</span></span>
<span><span class="op">)</span></span></code></pre></div>
    </div>

    <div class="section level2">
    <h2 id="arguments">Arguments<a class="anchor" aria-label="anchor" href="#arguments"></a></h2>
    <dl><dt>w</dt>
<dd><p>weight for mixture prior distribution</p></dd>


<dt>hr1</dt>
<dd><p>first assumed true treatment effect on HR scale for prior
distribution, see the <a href="https://sterniii3.github.io/drugdevelopR/articles/Introduction-to-drugdevelopR.html">vignette on priors</a>
as well as the <a href="https://web.imbi.uni-heidelberg.de/prior/" class="external-link">Shiny app</a> for
more details concerning the definition of a prior distribution.</p></dd>


<dt>hr2</dt>
<dd><p>second assumed true treatment effect on HR scale for prior distribution</p></dd>


<dt>id1</dt>
<dd><p>amount of information for <code>hr1</code> in terms of number of events</p></dd>


<dt>id2</dt>
<dd><p>amount of information for <code>hr2</code> in terms of number of events</p></dd>


<dt>d2min</dt>
<dd><p>minimal number of events for phase II</p></dd>


<dt>d2max</dt>
<dd><p>maximal number of events for phase II</p></dd>


<dt>stepd2</dt>
<dd><p>stepsize for the optimization over <code>d2</code></p></dd>


<dt>hrgomin</dt>
<dd><p>minimal threshold value for the go/no-go decision rule</p></dd>


<dt>hrgomax</dt>
<dd><p>maximal threshold value for the go/no-go decision rule</p></dd>


<dt>stephrgo</dt>
<dd><p>stepsize for the optimization over HRgo</p></dd>


<dt>adj</dt>
<dd><p>choose type of adjustment: <code>"multiplicative"</code>,
<code>"additive"</code>, <code>"both"</code> or <code>"all"</code>. When using "both",
<code>res[1,]</code> contains the results using the multiplicative method and <code>res[2,]</code>
contains the results using the additive method. When using "all", there are
also <code>res[3,]</code> and <code>res[4,]</code>, containing the results of a multiplicative
and an additive method which do not only adjust the treatment effect but
also the threshold value for the decision rule.</p></dd>


<dt>lambdamin</dt>
<dd><p>minimal multiplicative adjustment parameter lambda (i.e. use estimate with a retention factor)</p></dd>


<dt>lambdamax</dt>
<dd><p>maximal multiplicative adjustment parameter lambda (i.e. use estimate with a retention factor)</p></dd>


<dt>steplambda</dt>
<dd><p>stepsize for the adjustment parameter lambda</p></dd>


<dt>alphaCImin</dt>
<dd><p>minimal additive adjustment parameter alphaCI (i.e. adjust the lower bound of the one-sided confidence interval)</p></dd>


<dt>alphaCImax</dt>
<dd><p>maximal additive adjustment parameter alphaCI (i.e. adjust the lower bound of the one-sided confidence interval)</p></dd>


<dt>stepalphaCI</dt>
<dd><p>stepsize for alphaCI</p></dd>


<dt>alpha</dt>
<dd><p>one-sided significance level</p></dd>


<dt>beta</dt>
<dd><p>1-beta power for calculation of the number of events for phase III by Schoenfeld (1981) formula</p></dd>


<dt>xi2</dt>
<dd><p>event rate for phase II</p></dd>


<dt>xi3</dt>
<dd><p>event rate for phase III</p></dd>


<dt>c2</dt>
<dd><p>variable per-patient cost for phase II in 10^5 $</p></dd>


<dt>c3</dt>
<dd><p>variable per-patient cost for phase III in 10^5 $</p></dd>


<dt>c02</dt>
<dd><p>fixed cost for phase II in 10^5 $</p></dd>


<dt>c03</dt>
<dd><p>fixed cost for phase III in 10^5 $</p></dd>


<dt>K</dt>
<dd><p>constraint on the costs of the program, default: Inf, e.g. no constraint</p></dd>


<dt>N</dt>
<dd><p>constraint on the total expected sample size of the program, default: Inf, e.g., no constraint</p></dd>


<dt>S</dt>
<dd><p>constraint on the expected probability of a successful program, default: -Inf, e.g., no constraint</p></dd>


<dt>steps1</dt>
<dd><p>lower boundary for effect size category "small" in HR scale, default: 1</p></dd>


<dt>stepm1</dt>
<dd><p>lower boundary for effect size category "medium" in HR scale = upper boundary for effect size category "small" in HR scale, default: 0.95</p></dd>


<dt>stepl1</dt>
<dd><p>lower boundary for effect size category "large" in HR scale = upper boundary for effect size category "medium" in HR scale, default: 0.85</p></dd>


<dt>b1</dt>
<dd><p>expected gain for effect size category "small" in 10^5 $</p></dd>


<dt>b2</dt>
<dd><p>expected gain for effect size category "medium" in 10^5 $</p></dd>


<dt>b3</dt>
<dd><p>expected gain for effect size category "large" in 10^5 $</p></dd>


<dt>fixed</dt>
<dd><p>choose if true treatment effects are fixed or random, if TRUE hr1 is used as fixed effect</p></dd>


<dt>num_cl</dt>
<dd><p>number of clusters used for parallel computing, default: 1</p></dd>

</dl></div>
    <div class="section level2">
    <h2 id="value">Value<a class="anchor" aria-label="anchor" href="#value"></a></h2>
    

<p>The output of the function is a <code>data.frame</code> object containing the optimization results:</p><dl><dt>Adj</dt>
<dd><p>optimal adjustment parameter (lambda or alphaCI according to Method)</p></dd>
<dt>u</dt>
<dd><p>maximal expected utility under the optimization constraints, i.e. the expected utility of the optimal sample size and threshold value</p></dd>
<dt>HRgo</dt>
<dd><p>optimal threshold value for the decision rule to go to phase III</p></dd>

<dt>d2</dt>
<dd><p>optimal total number of events for phase II</p></dd>

<dt>d3</dt>
<dd><p>total expected number of events for phase III; rounded to next natural number</p></dd>

<dt>d</dt>
<dd><p>total expected number of events in the program; d = d2 + d3</p></dd>
<dt>n2</dt>
<dd><p>total sample size for phase II; rounded to the next even natural number</p></dd>

<dt>n3</dt>
<dd><p>total sample size for phase III; rounded to the next even natural number</p></dd>

<dt>n</dt>
<dd><p>total sample size in the program; n = n2 + n3</p></dd>

<dt>K</dt>
<dd><p>maximal costs of the program (i.e. the cost constraint, if it is set or the sum K2+K3 if no cost constraint is set)</p></dd>

<dt>pgo</dt>
<dd><p>probability to go to phase III</p></dd>

<dt>sProg</dt>
<dd><p>probability of a successful program</p></dd>

<dt>sProg1</dt>
<dd><p>probability of a successful program with "small" treatment effect in phase III</p></dd>

<dt>sProg2</dt>
<dd><p>probability of a successful program with "medium" treatment effect in phase III</p></dd>

<dt>sProg3</dt>
<dd><p>probability of a successful program with "large" treatment effect in phase III</p></dd>

<dt>K2</dt>
<dd><p>expected costs for phase II</p></dd>

<dt>K3</dt>
<dd><p>expected costs for phase III</p></dd>

</dl><p>and further input parameters. Taking <code>cat(comment())</code> of the
data frame lists the used optimization sequences, start and
finish date of the optimization procedure.</p>
    </div>
    <div class="section level2">
    <h2 id="references">References<a class="anchor" aria-label="anchor" href="#references"></a></h2>
    <p>IQWiG (2016). Allgemeine Methoden. Version 5.0, 10.07.2016, Technical Report. Available at <a href="https://www.iqwig.de/ueber-uns/methoden/methodenpapier/" class="external-link">https://www.iqwig.de/ueber-uns/methoden/methodenpapier/</a>, assessed last 15.05.19.</p>
<p>Preussler, S., Kirchner, M., Goette, H., Kieser, M. (2020). Optimal designs for phase II/III drug development programs including methods for discounting of phase II results. Submitted to peer-review journal.</p>
<p>Schoenfeld, D. (1981). The asymptotic properties of nonparametric tests for comparing survival distributions. Biometrika, 68(1), 316-319.</p>
    </div>

    <div class="section level2">
    <h2 id="ref-examples">Examples<a class="anchor" aria-label="anchor" href="#ref-examples"></a></h2>
    <div class="sourceCode"><pre class="sourceCode r"><code><span class="r-in"><span><span class="kw">if</span> <span class="op">(</span><span class="cn">FALSE</span><span class="op">)</span> <span class="fu">optimal_bias</span><span class="op">(</span>w <span class="op">=</span> <span class="fl">0.3</span>,                       <span class="co"># define parameters for prior</span></span></span>
<span class="r-in"><span>  hr1 <span class="op">=</span> <span class="fl">0.69</span>, hr2 <span class="op">=</span> <span class="fl">0.88</span>, id1 <span class="op">=</span> <span class="fl">210</span>, id2 <span class="op">=</span> <span class="fl">420</span>,      <span class="co"># (https://web.imbi.uni-heidelberg.de/prior/)</span></span></span>
<span class="r-in"><span>  d2min <span class="op">=</span> <span class="fl">20</span>, d2max <span class="op">=</span> <span class="fl">100</span>, stepd2 <span class="op">=</span> <span class="fl">5</span>,               <span class="co"># define optimization set for d2</span></span></span>
<span class="r-in"><span>  hrgomin <span class="op">=</span> <span class="fl">0.7</span>, hrgomax <span class="op">=</span> <span class="fl">0.9</span>, stephrgo <span class="op">=</span> <span class="fl">0.05</span>,     <span class="co"># define optimization set for HRgo</span></span></span>
<span class="r-in"><span>  adj <span class="op">=</span> <span class="st">"both"</span>,                                      <span class="co"># choose type of adjustment</span></span></span>
<span class="r-in"><span>  lambdamin <span class="op">=</span> <span class="fl">0.2</span>, lambdamax <span class="op">=</span> <span class="fl">1</span>, steplambda <span class="op">=</span> <span class="fl">0.05</span>, <span class="co"># define optimization set for lambda</span></span></span>
<span class="r-in"><span>  alphaCImin <span class="op">=</span> <span class="fl">0.025</span>, alphaCImax <span class="op">=</span> <span class="fl">0.5</span>,</span></span>
<span class="r-in"><span>  stepalphaCI <span class="op">=</span> <span class="fl">0.025</span>,                               <span class="co"># define optimization set for alphaCI</span></span></span>
<span class="r-in"><span>  alpha <span class="op">=</span> <span class="fl">0.025</span>, beta <span class="op">=</span> <span class="fl">0.1</span>, xi2 <span class="op">=</span> <span class="fl">0.7</span>, xi3 <span class="op">=</span> <span class="fl">0.7</span>,   <span class="co"># drug development planning parameters</span></span></span>
<span class="r-in"><span>  c2 <span class="op">=</span> <span class="fl">0.75</span>, c3 <span class="op">=</span> <span class="fl">1</span>, c02 <span class="op">=</span> <span class="fl">100</span>, c03 <span class="op">=</span> <span class="fl">150</span>,           <span class="co"># fixed/variable costs for phase II/III</span></span></span>
<span class="r-in"><span>  K <span class="op">=</span> <span class="cn">Inf</span>, N <span class="op">=</span> <span class="cn">Inf</span>, S <span class="op">=</span> <span class="op">-</span><span class="cn">Inf</span>,                        <span class="co"># set constraints</span></span></span>
<span class="r-in"><span>  steps1 <span class="op">=</span> <span class="fl">1</span>,                                        <span class="co"># define lower boundary for "small"</span></span></span>
<span class="r-in"><span>  stepm1 <span class="op">=</span> <span class="fl">0.95</span>,                                     <span class="co"># "medium"</span></span></span>
<span class="r-in"><span>  stepl1 <span class="op">=</span> <span class="fl">0.85</span>,                                     <span class="co"># and "large" effect size categories</span></span></span>
<span class="r-in"><span>  b1 <span class="op">=</span> <span class="fl">1000</span>, b2 <span class="op">=</span> <span class="fl">2000</span>, b3 <span class="op">=</span> <span class="fl">3000</span>,                   <span class="co"># define expected benefits </span></span></span>
<span class="r-in"><span>  fixed <span class="op">=</span> <span class="cn">FALSE</span>,                                     <span class="co"># true treatment effects are fixed/random</span></span></span>
<span class="r-in"><span>  num_cl <span class="op">=</span> <span class="fl">1</span><span class="op">)</span>                                        <span class="co"># number of coresfor parallelized computing </span></span></span>
<span class="r-in"><span>  </span></span>
</code></pre></div>
    </div>
  </main><aside class="col-md-3"><nav id="toc"><h2>On this page</h2>
    </nav></aside></div>


    <footer><div class="pkgdown-footer-left">
  <p></p><p>Developed by Stella Erdmann, Johannes Cepicka, Lukas D. Sauer.</p>
</div>

<div class="pkgdown-footer-right">
  <p></p><p>Site built with <a href="https://pkgdown.r-lib.org/" class="external-link">pkgdown</a> 2.0.7.</p>
</div>

    </footer></div>

  

  

  </body></html>

